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Abstract

Leumas, Jordan Kristopher. MS. The University of Memphis May 2014.
Characterization of Bone Abnormalities in Townes Sickle Cell Mice. Major Professor:
T. Kent Gartner, PhD

Sickle Cell Disease (SCD) is one of the most common severe monogenic
disorders in the world. The disease causes severe pain, inflammation, tissue ischemia,
and bone damage. The Townes mouse model of SCD has been useful in studying many
of the pathophysiologies of the disease but has not been evaluated as a model of SCDinduced bone abnormalities. The data presented in this study demonstrate that SCD
causes bone abnormalities in the Townes mouse model similar to those present in
humans. This study also evaluated the antioxidant agent N-acetyl-L- cysteine (NAC) as a
potential therapeutic agent for the progression of bone abnormalities in SCD mice.
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Introduction
Sickle cell disease (SCD) is one of the most common severe monogenic disorders
in the world affecting millions of people worldwide and as many as 100,000 people
in the United States. It can be characterized as a multisystem disease with acute
vaso-occlusive episodes leading to progressive organ damage. In 1949 Linus
Pauling termed SCD as the first “molecular disease” after observing the altered
electrophoretic properties of hemoglobin from the sickled erythrocytes (HbS). The
term “sickle cell disease” encompasses all the different genotypes that cause the
characteristic clinical manifestations; “sickle cell anemia” refers to homozygosity for
the mutant βs allele and is the most common form of the disease (Rees 2010). The
mutation in the β-globin gene is an adenine to thymine transversion of the 17th
nucleotide in the first exon of the human β-globin structural gene causing the sixth
amino acid in the protein to be changed from glutamic acid to valine (Bunn 1997).
The hydrophobic moiety resulting from the amino acid substitution presumably
causes the polymerization of adjacent hemoglobin molecules inside erythrocytes
(RBCs) under conditions of low oxygen pressure found in small veins. This
polymerization of HbS hemoglobin changes the cells’ flexibility and morphology
leading to cellular dehydration, oxidative stress, and the characteristic sickled shape
(Brittenham 1985). Sickling of the RBCs is the cause of all the endogenously
elicited deleterious effects of SCD.
The clinical manifestations and severity of the disease depend on several factors
including the specific genotype of the patient, the patient’s age at diagnosis, and
environmental factors including but not limited to diet, climate, and whether or not
1

the person is a smoker (Buchanan 2010). The pathology of the disease is also highly
variable but tissue damage can occur in the lungs, heart, kidneys, liver, spleen, and
bones in addition to other organs. Organ damage can be episodic or progressive with
some of the most common organ-related complications being severe pain crises,
acute chest syndrome, stroke, and priapism. Pulmonary hypertension, osteonecrosis,
chronic renal disease, and cognitive dysfunction are also common.
Two major pathophysiologies of sickle cell disease are hemolytic anemia and
vaso-occlusion. Hemolytic anemia is a result of HbS polymerization that causes
RBC sickling; the sickled RBCs undergo hemolysis thereby releasing hemoglobin.
The free hemoglobin in the circulation binds directly to nitric oxide thereby
depleting functional nitric oxide, and the free hemoglobin enhances reactive oxygen
species (ROS) production (Reiter 2002). ROS are chemically reactive molecules
that form as a natural byproduct of oxygen metabolism that can have important roles
in cell signaling. Increased amounts of ROS can damage cell structures and trigger
oxidative stress; HbS has been shown to increase levels of ROS, specifically
superoxide, peroxide, and hydroxyl radicals within erythrocytes of SCD patients
(Hebbel 1982). Nitric oxide (NO) is an important cellular messenger that has been
shown to selectively reduce endothelial expression of adhesion molecules. After
hemolysis, free hemoglobin scavenges NO leading to dioxygenation and
nitrosylation of NO resulting in endothelial dysfunction (De Caterina 1995). Thus,
free plasma hemoglobin leads to expression of endothelial adhesion molecules as
well as the generation of ROS leading to vaso-occlusion and further hemoloysis.
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The second major pathophysiology of SCD is vaso-occlusion. The pain thought
to result from vaso-occlusion may be caused by the ischemia, which results from
vascular obstruction by the sickled erythrocytes. HbS polymerization induces a
rigid, sickled shape in RBCs preventing them from passing through the vascular
lumens of very small veins. In addition to HbS polymerization, entrapment of the
RBCs in the microcirculation is also mediated by the inflammatory response (Rees
2010). Previous studies using transgenic sickle-cell mice have shown that treatment
with inflammatory drugs enhances erythrocyte adhesion within the vasculature
(Oxarogiagbon 2000; Frenette 2002). Vascular occlusion results from the interaction
between the endothelium and the circulating erythrocytes adherent to leucocytes
(Rees 2010). That interaction promotes occlusion by the erythrocyte/leukocyte
complexes, preventing sufficient blood flow, which in turn leads to ischemia.
Reperfusion can occur once the erythrocytes are pushed through the blood vessel,
but this can be problematic and result in further vascular damage from the sudden
turbulent blood flow that can rupture the already weakened vessels. This ischemiareperfusion cycle produces oxidative stress that can further activate the inflammatory
response by eliciting synthesis of inflammatory cytokines.
Life expectancy for SCD patients has increased over the past 25 years due to early
screening, prevention of lung infection in newborns, and improved management of
symptoms; many patients now survive into their fifth and sixth decades. This has led
to the characterization of SCD-induced bone abnormalities in human patients. In
addition to complications associated with hemolysis and vaso-occlusion, end-arterial
thromboses lead to tissue hypoxia and osteonecrosis while chronic hemolysis results
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in marrow hyperplasia with subsequent bone deformation (Miller 2006). As well as
osteonecrosis, SCD patients can suffer from osteoporosis and osteopenia that can
cause pain, deformity and fractures (Sarrai 2007). Bone necrosis has also been
correlated with iron overload to which SCD patients are prone due to frequent blood
transfusions. These transfusions introduce a much higher amount of iron (bound to
hemoglobin) than is required to maintain normal iron homeostasis. Rather than
being excreted, this excess iron accumulates in bones and other tissues (siderosis- the
accumulated iron resulting in siderosis is not bound to hemoglobin).
Cortical and trabecular bone abnormalities have been described as a consequence
of iron accumulation in mice with the associated involvement of enhanced ROS and
osteoclastogenic cytokines such as tumor necrosis factor alpha (TNF-α), receptor
activator of nuclear factor kappa B (RANK and RANKL), and interleukin-6 (IL-6)
(Tsay 2010). These bone pathologies are a significant contributor to patient
morbidity as they correlate to pain, fractures, deformities, and vertebral collapse
(Sarrai 2007). Bone composition is assessed by measuring bone mineral density
(BMD), the term describing the amount of mineral per square centimeter of bone, an
important indicator of osteoporosis. Dual-energy x-ray absorptiometry (DEXA) can
be used to measure BMD as well as bone mineral content (BMC), another important
index of bone composition, and is an important tool for measuring the SCD-induced
bone morphologies.
Currently the only cure for SCD is bone marrow transplantation. This is a risky
procedure with complications ranging from adverse radiation effects,
neurodevelopmental issues, strokes, and other complications. These complications

4

vary with the age of the patient and must be weighed carefully against the potential
benefits of the procedure (Buchanan 2010). While bone marrow transplantation has
been an effective cure, the small number of HLA matched donors keeps this route
closed to most patients. Patients unable to receive a bone-marrow transplant must
resort to therapeutic treatments such as blood transfusions, or hydroxycarbamide and
hydroxyurea which increase levels of fetal hemoglobin (HbF); all of which carry
their own risks and have variable efficacies.
The costs related to sickle cell disease are difficult to quantify because they can be
divided into many different categories with emergency department visits, in-patient
hospital stays, regular physician visits, and pharmaceuticals being a few of the major
categories. A research study conducted from 2001-2005 in Florida found that
average total costs per patient-month ranged from $892 to $2,853 depending on age
group (Kauf 2009). A more recent study collected data from 1996-2010 from
Florida, New Jersey, Missouri, Kansas, and Iowa and found that the average
quarterly costs of SCD patients ranged from $6,762- $14,511 depending on age and
iron chelation therapy (Blinder 2013). With an estimate of 70,000 people in the U.S.
suffering from SCD this translates into annual costs in excess of a billion dollars.
The un-assessed costs including days of work lost, and reduced productivity, lower
quality of life, and premature mortality augment that number.
Sickle cell disease is a genetic disorder characterized by broad-spectrum
inflammation, a component of the feedback loop involving vaso-occlusion and
hemolytic anemia. Further research into the effects of this inflammation is necessary
to advance our understanding of many of the phenotypes characteristic of the
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disease. Despite our increased understanding of many of the pathophysiologies
since the discovery of the disease in 1910, there is a dearth of effective treatment
options to alleviate, or at least ameliorate, the pain and organ damage caused by the
condition. An underlying goal of this proposal is to evaluate the ability of an antioxidant agent, N-Acetyl-L-Cysteine (NAC), to decrease the pathophysiological
changes on bones produced by the disease and to hopefully alleviate some of the
pain experienced by patients as a result.
Statement of Research Objectives
The overall goal of this thesis is to characterize the bone abnormalities
associated with SCD in the Townes SCD mouse model and to investigate the
effects, if any, of NAC on these SCD-induced bone morphologies. This will
allow the assessment of Townes mice to be used as a model of human SCDinduced bone abnormalities. Since there is a dearth of therapeutic treatments for
SCD there is a pressing need to characterize the effects of SCD on bones in a
mouse model. This will allow researchers to test potential therapeutic agents.
The overall goal was accomplished by fulfilling the following specific aims.
The first aim was the characterization of the mouse skeleton as a function
of whole-body irradiation. It is difficult to generate large numbers of SCD mice
by breeding due to early mortality associated with parturition of the mice. As
such, the mice used in the experiment were produced by bone marrow
transplantation (BMT) of healthy C57Bl/6 mice with marrow from Townes mice
expressing human HbS hemoglobin or Townes mice expressing normal human
hemoglobin, HbA. Bone marrow transplantation requires the mice to undergo
6

whole-body irradiation to eliminate their native marrow to facilitate replacement
with marrow from the donor mice. Therefore, it was necessary to investigate the
effects of whole-body irradiation on the skeleton to learn whether or not the
irradiation adversely affects the bones of the treated mice. This control has not
been described in the literature.
The second aim was characterization of the mouse skeleton as a function
of SCD. The skeletons were characterized using two different techniques. A low
voltage, low resolution PIXImus2 machine was used to measure bone
composition using dual-energy x-ray absorptiometry (DEXA). This method is
useful for determining the bone mineral density (BMD) and bone mineral content
(BMC) of the mice. The second technique was a three-point bending test used to
assess the biomechanical properties of the femurs of the mice. Finally, micro-CT
was used to give more detailed information about the L5 vertebrae (fifth lumbar
vertebrae) and femur including trabecular number, cortical thickness and virtual
3-D images of the L5 vertebrae and femur.
The third aim was to assess the effects of the anti-oxidant agent N-AcetylL-Cysteine (NAC) on the progression of bone abnormalities in SCD mice.
Reactive oxygen species (ROS) are produced in response to hemolysis, which
induces the inflammatory response that may be responsible, at least in part, for the
development of severe bone abnormalities. NAC replenishes intracellular
glutathione levels, a central component in the cellular defense against oxidative
stress and has been proven as a therapeutic agent in reducing ROS in human SCD
patients (Nur 2012). Additionally, it is already available as an orally-
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administered drug in humans. NAC will thus be evaluated as a possible
therapeutic agent for treating the symptoms of SCD on bone.
Materials and Methods
i.

Animals
All mice used in this study were obtained as 8-week-old female C57Bl/6

mice purchased from Jackson Labs. All bone marrow transplantations done to
produce the mice used in this study were performed at the University of North
Carolina at Chapel Hill. All mice used in this study were housed at the University
of Memphis and kept in Allentown Inc. cages with 3-4 mice per cage. Cages
were vented and kept under positive pressure with low-velocity filtered air to
reduce ammonia levels and the spread of communicable diseases spread by
aerosols. Animals were housed at 22̊C with a 12:12 hour dark/light cycle and fed
clean water and standard laboratory rodent chow.
The effects of irradiation on BMD was assessed as follows: 8 female
C57Bl/6 mice denoted as “wild type” (WT) were compared to 8 age and gender
matched C57Bl/6 mice which had previously undergone BMT with marrow from
another C57Bl/6 mouse. The transplanted mice are denoted as “bone marrow
transplants” (BMT). BMT recipient mice were lethally irradiated with 14 Gy (2
doses of 7 Gy 4 hours apart) to ablate bone marrow cells using a Cesium-137
irradiator (Markl irradiator; J.L. Shepherd & Associate). Recipient mice were
then injected via the retro-orbital sinus with 2x106 nucleated bone marrow cells
from WT controls. The mice were euthanized at 6.5 months of age according to
protocols approved by the University of Memphis IACUC committee (protocol
8

0699). The structures of the bones of the euthanized mice were evaluated using
DEXA.
The Townes mouse model of SCD have both human α- and β-globin genes
knocked into the mouse hemoglobin locus thereby knocking out the mouse α- and
β-hemoglobin genes, allowing the generation of littermate AA(mice expressing
only normal human HbA hemoglobin) and SS (mice expressing only human HbS)
mice after intercrossing Townes AS mice. Thirty 8 week-old female C57Bl/6
mice were purchased from Jackson labs and underwent bone marrow
transplantation at the University of North Carolina at Chapel Hill. Fifteen mice
received marrow from 2 Townes mice expressing only normal human hemoglobin
(HbA) and fifteen mice received marrow from 3 Townes mice expressing only
sickle human hemoglobin (HbS) using the method previously described. The
bone marrow was allowed to repopulate for 10 weeks after which blood was
harvested from each mouse by tail venipuncture. Hemolysate reagent (0.005 M
NaOH + 0.07% KCN HelenaLabs) was added to each blood sample after which
the samples were tested using gel electrophoresis to ensure that mice expressed
only human hemoglobin. All gel electrophoresis was performed by Dr. Erica
Sparkenbaugh at the University of North Carolina at Chapel Hill. All 15 of the
HbA mice expressed only normal human hemoglobin. Five of the 15 HbS mice
showed a small amount of mouse globin gene expression and thus were not
included in the experiment.
The NAC trial commenced 12 weeks post transplantation and the mice
were split into four groups. The 15 Townes HbA mice were split into two groups,
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8 mice receiving NAC injections (denoted “AN”) and 7 mice receiving PBS
injections (denoted “AP”). The 10 Townes HbS mice were split into two groups
of 5, one group receiving NAC injections (denoted “SN”) and the other receiving
PBS injections (denoted “SP”). NAC was generously donated by BioAdvantex
Pharma, Ontario, Canada and was kept under nitrogen to minimize oxidation.
Mass spectroscopy was used to evaluate the ratio of oxidized/reduced NAC
throughout the duration of the trial by Dr. Jin Xu, University of Massachusetts,
Lowell, MA.
Mice in the AN and SN groups were given the antioxidant NAC (100
mg/kg once per day) by subcutaneous injection (30 gauge ½ inch needle) five
consecutive days a week (Mon-Fri) for 10 weeks. Phosphate-buffered saline
(PBS) was used as the vehicle to solubilize the NAC (pH adjusted to 7.4 and then
filter sterilized). The mice in groups AP and SP were injected with PBS (vehicle)
subcutaneously five consecutive days a week for 10 weeks. All mice were
euthanized at the end of the 10 week trial according to the protocol approved by
the University of Memphis IACUC committee (protocol 0699).
ii.

Bone Analyses
DEXA analyses were performed at the University of Tennessee Health

Science Center using a Lunar PIXImus2 densitometer to measure BMD in g/cm2
and BMC in grams. Region(s) of interest (ROI) included the whole body
excluding the skull, cervical spines, lumbar spines, and femur + tibia complexes.
These data were collected and expressed graphically as the means ± standard
error.
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Mechanical testing was performed using an Instron Universal Test System
(Instron Corp., Norwood MA, model 5567). Three-point bending (gap size 7mm)
was done to determine the flexure stress of mouse femoral diaphysis. The load
was applied at a constant displacement of 5 mm/min to failure and the femurs
broke in the mid-diaphyseal region with data recorded as flexure stress in
megapascals (MPa). The software Bluehill v. 2.6 by Instron was used to gather
these data.
High-resolution micro-computed tomography (µCT40; Scanco Medical,
Basserdorf, Switzerland) was used to scan and characterize the bone
morphometric parameters of L5 and femurs. The spine samples were placed in a
12.3 mm-diameter sample holder filled with 75% ethanol and immobilized with
Styrofoam. The samples were scanned at 8-µm resolution at an energy of 55kVp,
integration time 300 ms, and an intensity of 109 µA. Bone morphometric
parameters were evaluated using a fixed Gaussian filter and a threshold of 220 for
trabecular bone and 260 for cortical bone.
iii.

Statistical Analysis
Results are presented as means with standard error (graphs) and mean ±

standard error of the mean (SEM) (tables). Differences between the groups were
evaluated by independent t test, and p values were considered significant at p <
0.05.
Osteopenia was defined as a T-score between -1.0 and -2.5 at one or more
anatomical sites and osteoporosis was defined as a T-score ≤ -2.5, consistent with
World Health Organization (WHO) criteria (Miller 2006). Due to the lack of
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BMD data for a global mouse population, the Townes HbA mice were used to
compute a wild type BMD average at each ROI. These averages were used to
make all osteopenic and osteoporotic evaluations.
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Chapter 1: Irradiation Effects on Bone
There is a high mortality rate associated with parturition of the newborn SCD
mice. For this reason, it was necessary to produce the mice used in the experiments
described here by bone marrow transplantation to have enough mice for statistical
significance. The procedure requires that the mice receive a lethal dose of whole body
irradiation, thereby eliminating their native marrow to facilitate replacement with marrow
from donor SCD or control mice.
Recently, a research group published a study providing data demonstrating that
low level abdominal irradiation produced detrimental effects on the bones of mice at sites
distant from radiation exposure. These effects would confound bone data collected from
the BMT SCD mice and thus warranted a study to test the effects of whole-body
irradiation on bone. This issue was addressed by comparing the BMD values obtained
from 8 female C57Bl/6 mice (WT) and 8 age and gender-matched C57Bl/6 bone marrow
transplantation mice (BMT). BMD measurements were taken from four regions of
interest (ROI) in all 16 mice and the averages are expressed graphically in Figure 1 and
numerically in Table S1. The ROI scanned include the whole body (excluding the skull),
excised cervical and lumbar spines, and the femur and tibia complexes. The femur and
tibia were selected as ROI based on previously described BMD deficiency of the femur
as a result of iron deposition, and because SCD patients require hip replacements with a
higher frequency than the population at large (Sarrai 2007).
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Results

Bone Mineral Density
0.07
0.06
grams/cm^2

0.05
0.04

WT

0.03

BMT

0.02
0.01
0
WB

CS

LS

F/T

Figure 1: Whole-body Irradiation Did Not Adversely Affect the BMD of BMT Mice.
There are no significant differences between the Bone mineral Density (BMD) means for
eight female C57Bl/6 mice (WT) compared to eight age-matched female C57Bl/6 bonemarrow transplanted mice (BMT) for whole body (WB), cervical spine (CS), lumbar spine
(LS), and Femur + Tibia (F/T) complexes as determined by DEXA. Data are presented as
means with standard error.

Discussion
Independent two-tailed t tests revealed no significant differences in BMD values
between WT and BMT mice. These results demonstrated that whole-body irradiation
used for bone marrow transplantation produces no loss of BMD. Based on these data, all
bone morphologies seen in BMT-produced SCD mice can be attributed solely to the
disease.
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Chapter 2: Bone Characterization
As the average lifespan of SCD patients increase, the effects of the disease on
bones have been documented in a few human studies. However, little research has been
done on treatments to mitigate this phenotype. While the Townes mouse model of SCD
has been shown to mimic the human disease in many ways, there has been no
quantification of the abnormal bone morphologies (if any) in Townes mice to assess their
usefulness for studying this aspect of the disease. This issue was addressed by
characterizing the skeletons of 5 female Townes HbS mice and 7 age and gender matched
Townes HbA mice. DEXA analyses of the skeletons facilitated comparison of the bone
structures of the mice. BMD and BMC measurements were taken from four ROI and the
averages are expressed graphically in Figures 2 and 3 and numerically in Tables S2 and
S3. The ROI scanned include the whole body (excluding the skull), the cervical and
lumbar spines, and the femur/tibia complexes. Additionally, micro-CT was performed on
the lumbar spines of PBS-treated Townes HbS and HbA mice and the results are
expressed numerically in Table 1. The 3-D renderings of the trabecular bone of L5 as
well as the cortical and trabecular bone for one femur of one PBS-treated Townes HbA
and one Townes HbS mouse are presented in Figure 4.
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Results

Bone Mineral Density
0.06

Grams/cm^2

0.05
0.04

*

*

*

AP

0.03

SP

0.02
0.01
0
WB

CS
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F/T

Figure 2: SCD Significantly Decreases BMD in Townes Mice
Bone Mineral Density (BMD) data for whole body (WB), cervical spine (CS), lumbar spine
(LS), and Femur + Tibia (F/T) complexes. X-ray densitometry was performed using seven
female Townes HbA mice (HbAA) and five age-matched female Townes HbS mice (HbSS).
The data in the graph are expressed as means with standard error as measured by DEXA.
Significant p values indicated by asterisks (WB p = 0.0002, LS p = 0.01, F/T p = 0.002).
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Bone Mineral Content
0.45
0.4
0.35

*

Grams

0.3
0.25

AP

0.2

SP

0.15
0.1

*

*

LS

F/T

0.05
0
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CS

Figure 3: SCD Significantly Lowers Bone Mineral Content (BMC) for all ROI
Excluding the Cervical Spine in Townes Mice
Bone Mineral Content (BMC) data for whole body (WB), cervical spine (CS), lumbar spine
(LS), and Femur + Tibia (F/T) complexes. X-ray densitometry was performed using seven
female Townes HbA mice (HbAA) and five age-matched female Townes HbS mice (HbSS).
The data in the graph are expressed as means with standard error as measured by DEXA.
Significant p values indicated by asterisks (WB p = 0.008, LS p = 0.005, F/T p = 0.008)
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Table 1. Micro-CT Comparison of Lumbar Vertebrae of PBS-Treated Townes
HbA and HbS Mice
SCD did not affect the Material BMD of Townes Mice
High-resolution micro-computed tomography means ± standard error of the mean (SEM)
for 11 lumbar spine vertebrae. Each set contains scans of 6 L5 vertebrae of PBS-injected
Townes HbA mice (AP) and 5 L5 vertebrae of PBS-injected HbS mice (SP). The data
were collected from a reconstruction of 100 slices from the anterior end of the vertebral
body. Two-tailed independent t tests were used to compare the means. Connectivity
Density is a measure of the degree to which a structure is multiply connected; Trabecular
separation is a measure of the thickness of the spaces between the trabeculae; Material
BMD is the BMD of the bone without the marrow. All micro-CT was performed by Dr.
Jinsong Huang at the University of Tennessee Health Science Center.
Lumbar Vertebrae Trabecular Data
Mean ± SEM
-3
Connectivity Density (mm )
AP
55.08 ± 4.62
SP
85.59 ± 3.54
-1
Trabecular Number (mm )
AP
3.43 ± 0.14
SP
4.03 ± 0.10
Trabecular Separation (mm)
AP
0.283 ± 0.014
SP
0.235 ± 0.0058
3
Material BMD (mg/cm )
AP
879.01 ± 7.52
SP
879.54 ± 6.21
Bone Volume/Total Volume(%)
AP
12.38 ± 1.15
SP
11.30 ± 0.61
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P-Value
0.0013

0.014

0.024

0.96

0.5

A. Townes HbA

B. Townes HbS

C. Townes HbA

D. Townes HbS

E. Townes HbA

F. Townes HbS

Figure 4. Micro-CT Analysis of Lumbar Vertebrae and Femurs
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G. Townes HbA

H. Townes HbS

Figure 4. Micro-CT Analysis of Lumbar Vertebrae and Femurs
Reconstructed images of the trabecular bone region of the lumbar vertebrae from Townes
HbA mouse (A) and Townes HbS mouse (B) (100 slices taken from the anterior end of the
vertebral body). Reconstructed sagittal sections of a femur from a Townes HbA mouse (C)
and a Townes HbS mouse (D). Reconstructed cross-sectional images from the middiaphyseal region of the femurs of Townes HbA (E) and Townes HbS (F). Reconstructed
trabecular bone from the heads of femurs of Townes Hb A mouse (G) and Townes HbS
mouse (H).

Discussion
An independent two-tailed t test was performed to assess whether or not there
were significant differences in the BMD and BMC values between Townes HbA and
HbS mice. For all ROI, excluding the cervical vertebrae, DEXA measurements showed
that the Townes mice with SCD had significantly lower BMD and BMC values than the
Townes mice expressing only normal human hemoglobin.
Micro-CT data of the lumbar spines directly contradicts the data obtained from
DEXA scans of the same region. The data presented in Table 1 indicate that PBS-treated
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Townes HbA mice had significantly lower connectivity density and trabecular number
and significantly higher trabecular separation than PBS-treated Townes HbS mice.
Additionally, there was no significant difference in the material BMD or the percentage
of bone volume/total volume between the two groups. These results are both surprising
and confusing as they go against expectations as well as the results obtained by DEXA
analysis. It is unclear why these results were obtained but the most- likely culprit is the
large amount of variability between individuals coupled with a small sample size. For all
measurements, there were several outliers in the AP group that were lower than the mean
by more than 1 standard deviation while there were several outliers in the SP group that
were higher than the mean by more than 1 standard deviation (data not shown).
Additionally, it must be noted that the micro-CT data came from analysis of the
trabecular region of the L5 vertebrae only while DEXA analysis looked at the vertebrae
of the entire lumbar spine region (both trabecular and cortical regions). If the BMD and
BMC of the L5 vertebrae in the Townes SCD mice were less affected than the other
lumbar vertebrae it would also explain the different results obtained from DEXA and
micro-CT analyses.
Images of the trabecular bone region of the lumbar vertebrae presented in Figure
4 are not representative of the AP and SP groups as a whole but were chosen to depict the
expected results of the study. Figure 4b shows that SCD reduces the trabecular number
and increases trabecular separation in Townes mice when compared to Townes mice
expressing only normal human hemoglobin. Only one femur from each group (AP and
SP) was analyzed and imaged using micro-CT and thus the images in Figure 4
C,D,E,F,G,&H cannot be taken as representative of the femurs of the groups as a whole.
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These images show that the femur of the SCD mouse had cortical thinning (Figure 4G)
and reduced trabecular number (Figure 4H).
Two studies looked at the prevalence of SCD patients with osteopenia and
osteoporosis. One study found that 79.6% of the SCD patients had abnormally low BMD
values while another study found that 72% of patients had abnormally low BMD values
(Miller 2006; Sarrai 2007). In the first study, researchers found 43.7% of the patients had
osteopenia and 35.9% had osteoporosis; similarly, the second study showed 31.3% of the
patients had osteopenia and 40.6% of the patients had osteoporosis at one or more
anatomical sites. Both studies found a high predilection for abnormal BMD in the
lumbar spine, affecting as much as 66% of patients.
Osteopenic and osteoporotic evaluations of the Townes mice used in this study
were made according to WHO criteria. At all four ROI scanned the Townes SCD mice
had a significantly greater proportion of abnormal BMD than the Townes HbAA mice.
The results are summarized in Table 2 below.

Table 2. Comparison of Occurrence of Abnormal BMD in Townes SS and AA Mice

Percentage and Classification of Abnormal BMD
WB
F+T
CS
LS
HbSS
Osteopenic
40%
20%
50%
50%
Osteoporotic
60%
70%
0%
30%
HbAA
Osteopenic
Osteoporotic

27%
0%
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13%
0%

20%
0%

13%
0%

These results indicate that the frequency of osteopenia and osteoporosis in the
Townes SCD model are similar to those seen in human SCD patients. However, there are
several factors that need to be taken into account when comparing the data. First, the
human trials consisted of patients with all different genotypes of SCD- HbSS, SC, and
Sβ-thalassemia- not only sickle cell anemia. Second, the sites tested in humans included
the lumbar spine, hip, femoral neck, and distal radius. Lastly, due to the lack of a global
mouse population BMD data, the Townes HbA mice were used to compute a wild type
BMD average at each ROI. Despite these differences, the results support the use of the
Townes SCD mouse as a model to examine the effects of SCD on bone and to test the
efficacy of potential therapeutic agents to ameliorate these phenotypes.
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Chapter 3: NAC Trial
Sickle cell disease results in the continuous hemolysis of erythrocytes as well as
inflammation caused by the hemolysis and the vaso-occlusion/reperfusion cycles. These
processes result in an increase in free radicals that can contribute to the damage
associated with the disease. Therefore, a trial was designed using N-acetyl-L-cysteine
(NAC), a commonly used antioxidant drug that may prevent or diminish damage caused
by free radicals. NAC is thought to increase glutathione levels in the body. Glutathione
is one of the major endogenous antioxidants that can neutralize free radicals.
While abnormal BMD and BMC levels have been documented in SCD patients,
the mechanistic cause of these morphologies is unknown. The cause is probably multifaceted and could include the bone marrow hyperplasia common to SCD patients and
bone marrow infarcts; oxidative stress and iron overload associated with hemolysis and
regular blood transfusions could also play a role. Tsay et al. (2010) demonstrated cortical
and trabecular thinning in an iron-overload mouse model as well as a rescue of these
phenotypes by NAC treatment. Additionally, the CURAMA study group showed a
reduced amount of oxidative stress and hemolysis in human SCD patients with the
administration of NAC over a 6-week trial period (Nur 2012). NAC was thus selected as
a potential therapeutic agent for this study that might ameliorate, or at least reduce, the
bone morphologies induced by SCD.
Two groups of mice were used in this trial: Townes HbS and Townes HbA. The
mice in each group were further subdivided into two groups: Townes HbS and HbA
injected with 0.1 mL PBS- the vehicle used to solubilize the NAC (SP and AP
respectively), and Townes HbS and HbA injected with NAC solubilized in PBS (SN and
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AN respectively). Mice were subcutaneously injected between the shoulder blades. The
trial lasted 10 weeks after which the mice were euthanized according to the protocol
approved by the University of Memphis IACUC committee (protocol 0699).
Immediately after death, the spleen, kidney, heart, and liver were removed from each
mouse and fixed in formalin for histological comparison. DEXA scanning was then
performed to obtain the BMD and BMC values of the mice. The ROI examined were the
whole body (excluding the skull), femur + tibia complexes, and the cervical and lumbar
spines. The spines of the mice were removed and stored at -80̊C for micro-CT scanning.
Additionally, one femur was removed from each mouse and wrapped in saline-soaked
gauze and stored at -80̊C for mechanical testing.

Results
Ten Townes HbS mice were used in this study, 5 vehicle-injected and 5 NACinjected. BMD and BMC measurements were taken and the results are expressed
numerically in Tables S4 and S5 and graphically in Figures 5 and 6 below.
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Figure 5: N-Acetyl-L-Cysteine Did Not Prevent or Diminish the Effects of SCD on BMD
(g/cm2)
Bone Mineral Density (BMD) data for whole body (WB), cervical spine (CS), lumbar spine
(LS), and Femur + Tibia (F/T) complexes are presented above. DEXA analyses were performed
using ten female Townes HbS mice. 5 mice were injected subcutaneously with PBS and the other
5 mice were injected subcutaneously with NAC solubilized in PBS. Mice were injected MondayFriday for 10 weeks. The data in the graph are expressed as means with standard error.
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Figure 6: N-Acetyl-L-Cysteine Did Not Prevent or Diminish the Effect of SCD on BMC (g)
Bone Mineral Content (BMC) data for whole body (WB), cervical spine (CS), lumbar spine (LS),
and Femur + Tibia (F/T) complexes are presented above. DEXA analyses were performed using
ten female Townes HbS mice. 5 mice were injected subcutaneously with PBS and the other 5
mice were subcutaneously injected with NAC solubilized in PBS. The mice were injected
Monday-Friday for 10 weeks. The data in the graph are expressed as means with standard error.

There were no significant differences in mean BMD or mean BMC values
between the Townes HbS mice injected with PBS versus those injected with NAC.
Townes HbA mice were also included in the trial as a control for the effects of
NAC in healthy mice. Seven mice were subcutaneously injected with 0.1 mL PBS (AP)
and the other 8 mice were subcutaneously injected with NAC solubilized in PBS (AN).
BMD and BMC measurements were taken and the results are expressed graphically in
Figures 7 and 8, and numerically in Tables S6 and S7.
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Figure 7: NAC Did Not Affect the BMD in the Townes HbA Mice (g/cm2)
Bone Mineral Density (BMD) data for whole body (WB), cervical vertebrae (CS), lumbar
vertebrae (LS), and Femur + Tibia (F/T) complexes are presented above. DEXA analyses were
performed using fifteen female Townes HbA mice. 7 mice were injected subcutaneously with
PBS and the other 8 mice were injected subcutaneously with NAC solubilized in PBS. Mice
were injected once/day Monday-Friday for 10 weeks. The data in the graph are expressed as
means with standard error.
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Figure 8: NAC Did Not Affect the BMC in the Townes HbA Mice (g)
Bone Mineral Content (BMC) data for whole body (WB), cervical vertebrae (CS), lumbar
vertebrae (LS), and Femur + Tibia (F/T) complexes are presented above. DEXA analyses were
performed using fifteen female Townes HbA mice. 7 mice were injected subcutaneously with
PBS and the other 8 mice were injected subcutaneously with NAC solubilized in PBS. Mice
were injected once/day Monday-Friday for 10 weeks. The data in the graph are expressed as
means with standard error.

There were no significant differences between the mean BMD or mean BMC
measurements between the Townes HbA mice injected with NAC and those injected with
PBS.
In addition to DEXA analysis, one femur from each mouse was mechanically
tested using an Instron Universal Test System (Instron Corp., Norwood MA, model
5567). The femurs were removed from each mouse and wrapped in saline-soaked gauze
and stored at -80̊C. Three-point bending was performed to failure (constant displacement
of 5mm/min, gap size of 7 mm) to determine the flexure stress of mouse femoral
diaphyses. The results are summarized in Table 3 below.
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Table 3. Mid-diaphysis Flexure Stress

Flexure Stress
Mean ± SEM
Group
(Mpa)
AP
110.08 ± 4.74
AN
97.51 ± 6.45
SP
90.54 ± 11.67
SN
67.29 ± 7.5
NAC Treatment Had No Beneficial Effect on Femur Strength in Townes Mice
Instron Universal Test System flexure data expressed in MPa as Mean ± SEM for 24 femurs.
Group AP contained 7 femurs from Townes HbA mice injected with PBS. Group AN contained
8 femurs from Townes HbA mice injected with NAC. Group SP contained 5 femurs from
Townes HbS mice injected with PBS. Group SN contained 4 femurs from Townes HbS mice
injected with NAC. Independent two-tailed t tests were performed for every group pair. Mean
flexure stress of the SN group was significantly less than the mean flexure stress for the AP group
(p=0.0003).
*One femur removed was from data set due to improper storage, leaving 4 femurs in group SN.

Independent two-tailed t-tests were performed to assess whether or not there was
a significant difference between any of the groups. Bone strength was significantly
reduced for the NAC injected mice both in the sickle cell and control groups. All p
values were greater than 0.05 except when groups AP v SN were compared (p value =
0.0003).

Discussion
These data demonstrated that the compound NAC did not prevent or diminish
bone abnormalities in the Townes SCD mice. However, there are several ways to
interpret these results. NAC acts by increasing levels of the endogenous anti-oxidant
30

glutathione and was chosen as a potential therapeutic agent due to a study by Tsay et al.
(2010) that showed that BMD and BMC loss in an iron-overload mouse model was
mitigated by subcutaneous injection of NAC. The protocol used by Tsay et al. was
followed in the study described here. It is possible that SCD’s deleterious effects on bone
work through a mechanism that is independent of any reactive oxygen species (ROS).
Infarcts leading to osteonecrosis and bone marrow hyperplasia may be the main culprits
in SCD patients’ bone morphologies. A second possibility is that the mice did not
receive a high-enough concentration of the NAC to produce measureable results. Mass
spectroscopy data show that 2/3s of the NAC was oxidized. NAC must be in its reduced
form in order to have any efficacy as an anti-oxidant, and so the mice in the experiment
were actually only receiving approximately 1/3 the dose of effective NAC. In retrospect,
increasing the concentration of NAC so that the mice would have received 100 mg/kg/d
of the reduced compound may have yielded different results.
The results of the three-point flexure stress test were also surprising. Independent
two-tailed t-test showed that there were no significant differences between SP and AP
groups, indicating that SCD did not adversely affect the strength of the femurs of Townes
mice. The expectation, of course, was that less force would be required to break the
femurs of SCD mice. Despite there being no statistically significant difference between
the SP and AP groups, the SCD mouse femurs did require ~18% less force to break than
the AP mouse femurs. This could indicate that the sample size was too small to provide
meaningful results.
A second surprising result was that the NAC-treated mouse femurs required less
force (on average) to break than their PBS-treated counterparts. There were no
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significant differences between SP and SN groups (p-value = 0.144) or AP and AN
groups (p-value = 0.15). However, SN femurs required on average ~25% less force to
break than SP femurs and AN femurs required on average ~11% less force to break than
AP femurs. This would seem to indicate that NAC actually negatively affected the
femoral strength. Indeed, although SP and AP groups were statistically similar (p-value=
0.112), the SN and AP groups were different (p-value = 0.000323). It is unclear why this
negative correlation between NAC-treatment and femoral strength was seen. One
possibility is the fact that both the SN and AN groups had some unusually low outliers
while the SP and AP groups had some unusually high outliers, skewing the results (data
not shown).
After the mice were euthanized the spleens were removed and weighed.
Splenomegaly is a well-documented phenotype in SCD mice and one of the key
differences between mouse models and human SCD patients, who present with splenic
atrophy. Mouse splenomegaly is due to the increased RBC and WBC production
necessitated by the constant hemolysis induced by SCD. Spleens of HbS mice were
between three and five times larger by weight than the spleens of HbA mice (data not
shown). A Student’s two-tailed t test was used to assess whether or not NAC had any
significant beneficial effects on the spleens of Townes SCD mice. Although there was no
statistically significant difference between the spleens of the PBS-injected and NACinjected SCD mice (p = 0.0846), NAC-treated SCD mouse spleens were 11% smaller on
average than the PBS-treated mice. These results may mean that NAC produced at least
a marginal benefit on SCD-induced splenomegaly. The reduction in spleen mass may
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indicate a reduction in hemolysis leading to a decreased demand for erythropoiesis on the
spleens of NAC-treated mice.

Overall Conclusion
The data presented in Chapter 1 demonstrate that whole-body irradiation has no
effect on bone morphologies in bone-marrow transplanted mice. This is important for the
study of SCD in mice since generating large numbers of SCD mice is difficult through
natural processes due to the high rate of mortality associated with parturition. These
results indicate that all bone morphologies seen in this study were due solely to SCD.
The mice used to examine the effects of whole-body irradiation were C57Bl/6 mice
transplanted with marrow from a C57Bl/6 donor which, unfortunately, is not truly the
correct control for this study. If possible in the future, comparison of the bones of
naturally-born Townes SCD mice with bones from mice that were transplanted with
marrow from a Townes SCD donor would give more conclusive evidence that wholebody irradiation has no effect on BMD or BMC.
Chapter 2 examines the effect of SCD on the bones and the results support the
conclusion that the Townes mouse model is an appropriate system in which to study these
SCD-induced morphologies. This chapter characterizes the effects of SCD on BMD and
BMC in the Townes model and also provides detailed images of the diseases’ effects on
the lumbar vertebrae and femurs. Before this study there were insufficient data in the
literature characterizing the development of bone abnormalities in SCD mouse models.
The conflicting data from the DEXA and micro-CT analyses should be examined in the
future with a larger study to ensure that a small sample size is not a confounding factor.
However, despite the differences, this study indicates that the effects of SCD on the
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bones of mice are similar to the effects seen in human patients. In addition, the Townes
model provides a potentially useful vehicle for testing the effects of potential SCD
therapeutic agents on the development of SCD induced bone abnormalities.
Finally, Chapter 3 examines the ability of the antioxidant agent NAC to prevent or
diminish the effects of SCD on the bones of Townes mice. The data collected in this
study suggest that NAC has no therapeutic efficacy in reducing SCD induced bone
abnormalities. These results were surprising as they conflicted with results obtained in a
previous study performed in this lab. Confounding factors include the small sample size
as well as the heavily-oxidized state of the NAC, which mitigates its antioxidant
properties. Despite the results obtained in this study, NAC may be a beneficial
therapeutic agent for other SCD phenotypes as the disease is being understood more and
more as a chronic inflammatory disease.
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Supplemental Data
Table S1. Comparison of PIXImus2 BMD in WT and BMT mice (g/cm2)
Whole-body irradiation did not adversely affect the BMD of BMT mice. (g/cm2)
PIXImus2 (DEXA) BMD means ± standard error of the mean (SEM) for the scans of 16
whole bodies (without skulls), cervical regions of 16 spines, lumbar regions of 16 spines,
and 16 femur and tibia complexes. Each set contains 8 C57Bl/6 mice (WT) and 8 C57Bl/6
bone marrow transplanted mice (BMT). The same region of interest (ROI) was used for all
members of a set of measurements. Two-tailed independent t-tests were used to compare
means. For all ROI p values showed no significant difference between groups.

Bone Mineral Density
Mean ± SEM
Whole Body
WT
BMT
Cervical Spine
WT
BMT
Lumbar Spine
WT
BMT
Femur+Tibia
WT
BMT

P Value
0.107

0.051963 ± .0008
0.050354 ± .0004
0.141
0.051614 ± .002
0.057625 ± .003
0.428
0.054 ± .002
0.0525 ± .001
0.617
0.058675 ± .001
0.059325 ± .0007
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Table S2. Comparison of PIXImus2 BMD in Townes HbA and HbS Mice (g/cm2)
SCD significantly lowers Bone Mineral Density (BMD) in Townes mice (g/cm2)
DEXA BMD means (± SEM) for the scans of 12 whole bodies (without skulls), cervical
regions of 12 spines, lumbar regions of 12 spines, and 12 femur and tibia complexes. Each
set contains 7 PBS-injected Townes HbA (normal) mice (AP) and 5 PBS-injected Townes
(sickle) HbS mice. The same region of interest (ROI) was used for all members of a set of
measurements. BMD means were significantly lower for the whole mice, lumbar vertebrae,
and the femur/tibia complexes in the sickle cell mouse group (SP).

ROI
Whole Body
AP
SP
Cervical Spine
AP
SP
Lumbar Spine
AP
SP
Femur/Tibia
AP
SP

Bone Mineral Density
Mean ± SEM

P Value
0.000276

0.0438 ± .00056
0.0396 ± .00031
0.0938
0.0439 ± .0021
0.0385 ± .00095
0.0105
0.0445 ± .00085
0.0405 ± .00064
0.00234
0.0485 ± .00064
0.043 ± .0012
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Table S3. Comparison of PIXImus2 BMC in Townes HbA and HbS Mice (g)
SCD significantly lowers Bone Mineral Content (BMC) for all ROI excluding the
Cervical Spine in Townes Mice (g)
DEXA BMC means (± SEM) for the scans of 12 whole bodies (without skulls), 12 cervical
spine vertebrae, 12 lumbar spine vertebrae, and 12 femur and tibia complexes. Each set
contains 7 PBS-injected Townes HbA mice (AP) and 5 PBS-injected Townes HbS mice
(SP). The same region of interest (ROI) was used for all members of a set of measurements.
There was significantly less mean BMC in the sickle cell group (SP) compared to the normal
mice (AP) for the whole body, lumbar vertebrae, and the long bones.

ROI
WB
AP
SP
Cervical Spine
AP
SP
Lumbar Spine
AP
SP
Femur/Tibia
AP
SP

Bone Mineral Content
Mean ± SEM

P Value
0.00869

0.32 ± .0072
0.282 ± .0077
0.756
0.0203 ± .0029
0.0215 ± .00037
0.00507
0.0336 ± .00083
0.0288 ± .00086
0.00805
0.0388 ± .00083
0.034 ± .0011
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Table S4. Comparison of BMD for PBS-injected vs. NAC-injected Townes HbS mice (g/cm2)
N-Acetyl-L-Cysteine Shows No Efficacy in Reducing SCD’s Effects on BMD (g/cm2)
DEXA BMD means (± SEM) for the scans of 10 whole bodies (without skulls), cervical vertebrae
of 10 spines, lumbar vertebrae of 10 spines, and 10 femur and tibia complexes. Each set contains
5 PBS-injected Townes HbS mice (SP) and 5 NAC-injected Townes HbS mice (SN). The same
region of interest (ROI) was used for all members of a set of measurements. Two-tailed
independent t-tests were used to compare means. For all ROI p values showed no significant
difference between the groups.

ROI
Whole Body
SN
SP
Cervical Spine
SN
SP
Lumbar Spine
SN
SP
Femur/Tibia
SN
SP

Bone Mineral Density
Mean ± SEM

P Value
0.462

0.0389 ± .00079
0.0396 ± .00031
0.167
0.0429 ± .0024
0.0385 ± .00095
0.783
0.0409 ± .00093
0.0405 ± .00064
0.372
0.0409 ± .0016
0.043 ± .0012
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Table S5. Comparison of BMC for PBS-injected vs. NAC-injected Townes HbS mice (g)
N-Acetyl-L-Cysteine Shows No Efficacy in Reducing SCD’s Effects on BMC (g)
DEXA BMC means (± SEM) for the scans of 10 whole bodies (without skulls), cervical vertebrae
of 10 spines, lumbar vertebrae of 10 spines, and 10 femur and tibia complexes. Each set contains
5 PBS-injected Townes HbS mice (SP) and 5 NAC-injected Townes HbS mice (SN). The same
region of interest (ROI) was used for all members of a set of measurements. Two-tailed
independent t-tests were used to compare means. For all ROI p values showed no significant
difference between the groups.

ROI
Whole Body
SN
SP
Cervical Spine
SN
SP
Lumbar Spine
SN
SP
Femur/Tibia
SN
SP

Bone Mineral Content
Mean ± SEM

P Value
0.361

0.27 ± .00716
0.282 ± .00773
0.363
0.019 ± .00229
0.0215 ± .000374
0.823
0.0291 ± .00078
0.0288 ± .000856
0.287
0.0312 ± .00192
0.034 ± .00106
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Table S6. Comparison of BMD for PBS-injected vs. NAC-injected Townes HbA mice
(g/cm2)
NAC Shows No Effect on BMD in Townes HbA Mice (g/cm2)
DEXA BMD means (± SEM) for the scans of 15 whole bodies (without skulls), cervical vertebrae
of 15 spines, lumbar vertebrae of 15 spines, and 15 femur and tibia complexes. Each set contains
7 PBS-injected Townes HbA mice (AP) and 8 NAC-injected Townes HbA mice (AN). The same
region of interest (ROI) was used for all members of a set of measurements. There was no
significant difference between the mean BMD of the AP and AN groups.

ROI
Whole Body
AP
AN
Cervical Spine
AP
AN
Lumbar Spine
AP
AN
Femur/Tibia
AP
AN

Bone Mineral Density
Mean ± SEM

P Value
0.671

0.0438 ± .00056
0.0435 ± .00058
0.408
0.0439 ± .0021
0.0467 ± .0022
0.547
0.0445 ± .00085
0.0452 ± .00064
0.0967
0.0485 ± .00064
0.0471 ± .0004
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Table S7. Comparison of BMC for PBS-injected vs. NAC-injected Townes HbA mice (g)
NAC Shows No Effect on BMC in Townes HbA Mice (g)
DEXA BMC means (± SEM) for the scans of 15 whole bodies (without skulls), cervical vertebrae
of 15 spines, lumbar vertebrae of 15 spines, and 15 femur and tibia complexes. Each set contains
7 PBS-injected Townes HbA mice (AP) and 8 NAC-injected Townes HbA mice (AN). The same
region of interest (ROI) was used for all members of a set of measurements. There was no
significant difference between the mean BMC for the PA and AN groups.

ROI
Whole Body
AP
AN
Cervical Spine
AP
AN
Lumbar Spine
AP
AN
Femur/Tibia
AP
AN

Bone Mineral Content
Mean ± SEM

P Value
0.902

0.32 ± .0072
0.321 ± .0059
0.104
0.0203 ± .0029
0.0265 ± .0017
0.705
0.0336 ± .00083
0.034 ± .00083
0.896
0.0388 ± .00083
0.0389 ± .00068
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a.

b.

c.

d.
Figure S1. Histological Comparisons of PBS-injected Townes HbA and HbS organs
All tissues samples processed with Shandon Citadel 2000 Automatic Tissue Processor, embedded
in paraffin using the Leica EG1160 Tissue Embedding Station, sectioned using a Microm HM
360 Rotary Microtome, and stained using a Leica XL ST5010. Slides were imaged using a Nikon
Eclipse 800/C-1 microscope and Nikon Digital Camera DXM1200F using ACT-1 software. All
sectioning and imaging was performed by Lauren Thompson at the University of Memphis. (a)
Heart muscle of AP mouse (left) and SP mouse (right). (b) Kidney tissue of AP mouse (left) and
SP mouse (right). (c) Liver tissue of AP mouse (left) and SP mouse (right). (d) Spleen tissue of
AP mouse (left) and SP mouse (right)
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a.

b.

c.

d.
Figure S2. Histological Comparisons of PBS-injected and NAC-injected Townes HbS
organs
All tissues samples processed with Shandon Citadel 2000 Automatic Tissue Processor, embedded
in paraffin using the Leica EG1160 Tissue Embedding Station, sectioned using a Microm HM
360 Rotary Microtome, and stained using a Leica XL ST5010. Slides were imaged using a Nikon
Eclipse 800/C-1 microscope and Nikon Digital Camera DXM1200F using ACT-1 software. All
sectioning and imaging was performed by Lauren Thompson at the University of Memphis. (a)
Heart muscle of SP mouse (left) and SN mouse (right). (b) Kidney tissue of SP mouse (left) and
SN mouse (right). (c) Liver tissue of SP mouse (left) and SN mouse (right). (d) Spleen tissue of
SP mouse (left) and SN mouse (right)
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AP v AN Heart

AP v AN Kidney

AP v AN Liver

AP v AN Spleen
Figure S3. Histological Comparisons of PBS-injected and NAC-injected Townes HbA
organs
All tissues samples processed with Shandon Citadel 2000 Automatic Tissue Processor, embedded
in paraffin using the Leica EG1160 Tissue Embedding Station, sectioned using a Microm HM
360 Rotary Microtome, and stained using a Leica XL ST5010. Slides were imaged using a Nikon
Eclipse 800/C-1 microscope and Nikon Digital Camera DXM1200F using ACT-1 software. All
sectioning and imaging was performed by Lauren Thompson at the University of Memphis. (a)
Heart muscle of AP mouse (left) and AN mouse (right). (b) Kidney tissue of AP mouse (left) and
AN mouse (right). (c) Liver tissue of AP mouse (left) and AN mouse (right). (d) Spleen tissue of
AP mouse (left) and AN mouse (right)

44

References
Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS. 2013. Age-related
treatment patterns in sickle cell disease patients and the associated sickle cell
complications and healthcare costs. Pediatr Blood Cancer .
Brittenham GM, Schechter AN, Noguchi CT. 1985. Hemoglobin S polymerization:
Primary determinant of the hemolytic and clinical severity of the sickling syndromes.
Blood 65(1):183-9.
Buchanan G, Vichinsky E, Krishnamurti L, Shenoy S. 2010. Severe sickle cell disease-pathophysiology and therapy. Biol Blood Marrow Transplant 16(1 Suppl):S64-7.
Bunn HF. 1997. Pathogenesis and treatment of sickle cell disease. N Engl J Med
337(11):762-9.
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA,Jr,
Shin WS, Liao JK. 1995. Nitric oxide decreases cytokine-induced endothelial activation.
nitric oxide selectively reduces endothelial expression of adhesion molecules and
proinflammatory cytokines. J Clin Invest 96(1):60-8.
Frenette PS. 2002. Sickle cell vaso-occlusion: Multistep and multicellular paradigm. Curr
Opin Hematol 9(2):101-6.
Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. 1982. Spontaneous oxygen radical
generation by sickle erythrocytes. J Clin Invest 70(6):1253-9.
Jia D, Gaddy D, Suva LJ, Corry PM. 2011. Rapid loss of bone mass and strength in mice
after abdominal irradiation. Radiat Res 176(5):624-35.
Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. 2009. The cost of health
care for children and adults with sickle cell disease. Am J Hematol 84(6):323-7.
Miller RG, Segal JB, Ashar BH, Leung S, Ahmed S, Siddique S, Rice T, Lanzkron S.
2006. High prevalence and correlates of low bone mineral density in young adults with
sickle cell disease. Am J Hematol 81(4):236-41.
Nur E, Brandjes DP, Teerlink T, Otten HM, Oude Elferink RP, Muskiet F, Evers LM, ten
Cate H, Biemond BJ, Duits AJ, Schnog JJ; CURAMA study group. N-acetylcysteine
reduces oxidative stress in sickle cell patients. Ann Hematol. 2012 Jul;91(7):1097-105.
doi: 10.1007/s00277-011-1404-z. Epub 2012 Feb 10. PubMed PMID: 22318468;
PubMed Central PMCID: PMC3368118.

45

Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. 2000.
Reperfusion injury pathophysiology in sickle transgenic mice. Blood 96(1):314-20.
Rees DC, Williams TN, Gladwin MT. 2010. Sickle-cell disease. Lancet 376(9757):201831.
Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO,3rd, Schechter AN, Gladwin
MT. 2002. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.
Nat Med 8(12):1383-9.
Ryan TM, Ciavatta DJ, Townes TM. 1997. Knockout-transgenic mouse model of sickle
cell disease. Science 278(5339):873-6.
Sarrai M, Duroseau H, D'Augustine J, Moktan S, Bellevue R. 2007. Bone mass density in
adults with sickle cell disease. Br J Haematol 136(4):666-72.
Tsay J, Yang Z, Ross FP, Cunningham-Rundles S, Lin H, Coleman R, Mayer-Kuckuk P,
Doty SB, Grady RW, Giardina PJ, et al. 2010. Bone loss caused by iron overload in a
murine model: Importance of oxidative stress. Blood 116(14):2582-9.
Zhou Z, Behymer M, Guchhait P. 2011. Role of extracellular hemoglobin in thrombosis
and vascular occlusion in patients with sickle cell anemia. Anemia 2011:918916.

46

